Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{166454,
        author = {Mr. Rohit  Shivcharan Patil and HEMANT KAILAS PAWAR and Harshal Sanjiv Suryawanshi and Khushi Sharad Patil},
        title = {A New Era in Pharmaceutical Law: Reviewing Recent Amendments and Developments},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {2},
        pages = {1071-1075},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=166454},
        abstract = {This review paper, titled "A New Era in Pharmaceutical Law: Reviewing Recent Amendments and Developments," provides a comprehensive analysis of the latest changes and advancements in pharmaceutical jurisprudence. The pharmaceutical industry is highly regulated, with laws and regulations evolving to keep pace with scientific progress, public health needs, and technological innovations. This paper examines recent amendments in drug approval processes, updates in patent laws, and new regulations for digital health and e-pharmacies. It also explores developments in good manufacturing practices (GMP), pharmacovigilance, and drug safety. 
Additionally, the paper highlights regulatory pathways for biologics and biosimilars, changes in intellectual property rights (IPR), and efforts towards global harmonization of pharmaceutical regulations. By reviewing these recent legal changes and their implications, this paper aims to provide a valuable resource for professionals and scholars in the pharmaceutical field, fostering a deeper understanding of the dynamic legal environment shaping the industry.
},
        keywords = {},
        month = {July},
        }